PMP22 and neurodegenerative disease: The relatively milder increase in plasma NfL compared to other neurodegenerative disease models with robust increases, such as amyotrophic lateral sclerosis (ALS) (40), corresponds to clinical observations that patients with CMT1A show moderate NfL level elevation (28), whereas patients with ALS show a robust increase (41).